Literature DB >> 27319223

Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Julia E Vela Ramirez, Lorraine T Tygrett, Jihua Hao, Habtom H Habte, Michael W Cho, Neil S Greenspan, Thomas J Waldschmidt, Balaji Narasimhan.   

Abstract

Biodegradable polymeric nanoparticle-based subunit vaccines have shown promising characteristics by enhancing antigen presentation and inducing protective immune responses when compared with soluble protein. Specifically, polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) have been shown to successfully encapsulate and release antigens, activate B and T cells, and induce both antibody- and cell-mediated immunity towards a variety of immunogens. One of the characteristics of strong thymus-dependent antibody responses is the formation of germinal centers (GC) and the generation of GC B cells, which is part of the T helper cell driven cellular response. In order to further understand the role of nanovaccines in the induction of antigen-specific immune responses, their ability to induce germinal center B cell formation and isotype switching and the effects thereof on serum antibody responses were investigated in these studies. Polyanhydride nanovaccines based on 1,6-bis(p-carboxyphenoxy)hexane and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane were used to subcutaneously administer a viral antigen. GC B cell formation and serum antibody responses induced by the nanovaccines were compared to that induced by alum-based vaccine formulations. It was demonstrated that a single dose of polyanhydride nanovaccines resulted in the formation of robust GCs and serum antibody in comparison to that induced by the alum-based formulation. This was attributed to the sustained release of antigen provided by the nanovaccines. When administered in a multiple dose regimen, the highest post-immunization titer and GC B cell number was enhanced, and the immune response induced by the nanovaccines was further sustained. These studies provide foundational information on the mechanism of action of polyanhydride nanovaccines.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27319223      PMCID: PMC5438750          DOI: 10.1166/jbn.2016.2242

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  35 in total

Review 1.  Improving vaccine performance with adjuvants.

Authors:  F R Vogel
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

Review 2.  T follicular helper cell differentiation, function, and roles in disease.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

3.  Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.

Authors:  J E Vela Ramirez; R Roychoudhury; H H Habte; M W Cho; N L B Pohl; B Narasimhan
Journal:  J Biomater Sci Polym Ed       Date:  2014-07-28       Impact factor: 3.517

Review 4.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

5.  Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles.

Authors:  Kathleen A Ross; Hyelee Loyd; Wuwei Wu; Lucas Huntimer; Michael J Wannemuehler; Susan Carpenter; Balaji Narasimhan
Journal:  J Biomed Mater Res A       Date:  2014-02-04       Impact factor: 4.396

6.  Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using "pathogen-like" amphiphilic polyanhydride nanoparticles.

Authors:  Ana V Chavez-Santoscoy; Rajarshi Roychoudhury; Nicola L B Pohl; Michael J Wannemuehler; Balaji Narasimhan; Amanda E Ramer-Tait
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

7.  Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens.

Authors:  Brenda Carrillo-Conde; Elise Schiltz; Jing Yu; F Chris Minion; Gregory J Phillips; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2010-02-01       Impact factor: 8.947

8.  Dynamic signaling by T follicular helper cells during germinal center B cell selection.

Authors:  Ziv Shulman; Alexander D Gitlin; Jason S Weinstein; Begoña Lainez; Enric Esplugues; Richard A Flavell; Joseph E Craft; Michel C Nussenzweig
Journal:  Science       Date:  2014-08-29       Impact factor: 47.728

9.  Effect of nanovaccine chemistry on humoral immune response kinetics and maturation.

Authors:  Shannon L Haughney; Kathleen A Ross; Paola M Boggiatto; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Nanoscale       Date:  2014-11-21       Impact factor: 7.790

10.  Antigen depot is not required for alum adjuvanticity.

Authors:  Sharon Hutchison; Robert A Benson; Vivienne B Gibson; Abigail H Pollock; Paul Garside; James M Brewer
Journal:  FASEB J       Date:  2011-11-21       Impact factor: 5.191

View more
  10 in total

1.  Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery.

Authors:  Timothy M Brenza; Benjamin W Schlichtmann; Biju Bhargavan; Julia E Vela Ramirez; Rainie D Nelson; Matthew G Panthani; JoEllyn M McMillan; Balaraman Kalyanaraman; Howard E Gendelman; Vellareddy Anantharam; Anumantha G Kanthasamy; Surya K Mallapragada; Balaji Narasimhan; Georgette D Kanmogne
Journal:  J Biomed Mater Res A       Date:  2018-10-26       Impact factor: 4.396

2.  The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Authors:  Emad I Wafa; Sean M Geary; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

3.  pH-Responsive Microencapsulation Systems for the Oral Delivery of Polyanhydride Nanoparticles.

Authors:  Lindsey A Sharpe; Julia E Vela Ramirez; Olivia M Haddadin; Kathleen A Ross; Balaji Narasimhan; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2018-02-21       Impact factor: 6.988

Review 4.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

5.  Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Authors:  Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga
Journal:  J Immunol       Date:  2021-04-07       Impact factor: 5.422

6.  Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.

Authors:  Danielle A Wagner-Muñiz; Shannon L Haughney; Sean M Kelly; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

7.  Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf.

Authors:  Jodi L McGill; Sean M Kelly; Pankaj Kumar; Savannah Speckhart; Shannon L Haughney; Jamie Henningson; Balaji Narasimhan; Randy E Sacco
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

8.  Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.

Authors:  Zeb R Zacharias; Kathleen A Ross; Emma E Hornick; Jonathan T Goodman; Balaji Narasimhan; Thomas J Waldschmidt; Kevin L Legge
Journal:  Front Immunol       Date:  2018-08-28       Impact factor: 7.561

Review 9.  Polymeric nanoparticle vaccines to combat emerging and pandemic threats.

Authors:  David Wibowo; Sytze H T Jorritsma; Zennia Jean Gonzaga; Benjamin Evert; Shuxiong Chen; Bernd H A Rehm
Journal:  Biomaterials       Date:  2020-12-10       Impact factor: 12.479

Review 10.  Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies.

Authors:  Luman Liu; Prakash G Kshirsagar; Shailendra K Gautam; Mansi Gulati; Emad I Wafa; John C Christiansen; Brianna M White; Surya K Mallapragada; Michael J Wannemuehler; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Aliasger K Salem; Balaji Narasimhan; Maneesh Jain
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.